Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980669947> ?p ?o ?g. }
- W2980669947 endingPage "104685" @default.
- W2980669947 startingPage "104685" @default.
- W2980669947 abstract "Cyclophosphamide (CPA) is one of the most successful anticancer prodrugs that becomes effective after biotransformation in the liver resulting in the toxic metabolite acrolein. Cancer is often accompanied by thromboembolic events, which might be a result of dysfunctional endothelial cells due to CPA treatment. Here, the effect of 1 mM CPA or acrolein (10/50/100/500 μM) on human umbilical vein endothelial cells (HUVECs) was analyzed after two days of treatment. The addition of CPA or 10 μM acrolein did not affect HUVECs. However, concentrations of 100 μM and 500 μM acrolein significantly reduced the number of adherent cells by 86 ± 13% and 99 ± 1% and cell viability by 51 ± 29% and 93 ± 8% compared to the control. Moreover, pronounced stress fibers as well as multiple nuclei were observed and von Willebrand factor (vWF) was completely released. Lactate dehydrogenase was 8.5 ± 7.0-fold and 252.9 ± 42.9-fold increased showing a loss of cell membrane integrity. The prostacyclin and thromboxane secretion was significantly increased by the addition of 500 μM acrolein (43.1 ± 17.6-fold and 246.4 ± 106.3-fold) indicating cell activation/pertubation. High doses of acrolein led to HUVEC death and loss of vWF production. This effect might be associated with the increased incidence of thromboembolic events in cancer patients treated with high doses of CPA." @default.
- W2980669947 created "2019-10-25" @default.
- W2980669947 creator A5003580737 @default.
- W2980669947 creator A5031445293 @default.
- W2980669947 creator A5039184690 @default.
- W2980669947 creator A5059256469 @default.
- W2980669947 creator A5065284334 @default.
- W2980669947 creator A5068582168 @default.
- W2980669947 creator A5069104759 @default.
- W2980669947 creator A5076408652 @default.
- W2980669947 creator A5090259400 @default.
- W2980669947 date "2020-02-01" @default.
- W2980669947 modified "2023-10-16" @default.
- W2980669947 title "Effects of acrolein in comparison to its prodrug cyclophosphamide on human primary endothelial cells in vitro" @default.
- W2980669947 cites W1563213082 @default.
- W2980669947 cites W1574214553 @default.
- W2980669947 cites W1590845064 @default.
- W2980669947 cites W1963661801 @default.
- W2980669947 cites W1964505940 @default.
- W2980669947 cites W1972773259 @default.
- W2980669947 cites W1992248095 @default.
- W2980669947 cites W1994736776 @default.
- W2980669947 cites W1995577444 @default.
- W2980669947 cites W1998794592 @default.
- W2980669947 cites W2016065545 @default.
- W2980669947 cites W2022677287 @default.
- W2980669947 cites W2028497575 @default.
- W2980669947 cites W2035495649 @default.
- W2980669947 cites W2039910421 @default.
- W2980669947 cites W2051574849 @default.
- W2980669947 cites W2065470651 @default.
- W2980669947 cites W2070025346 @default.
- W2980669947 cites W2076744430 @default.
- W2980669947 cites W2078032620 @default.
- W2980669947 cites W2078557482 @default.
- W2980669947 cites W2086104559 @default.
- W2980669947 cites W2087211939 @default.
- W2980669947 cites W2089289934 @default.
- W2980669947 cites W2092296830 @default.
- W2980669947 cites W2118143284 @default.
- W2980669947 cites W2122462056 @default.
- W2980669947 cites W2123626152 @default.
- W2980669947 cites W2126350789 @default.
- W2980669947 cites W2140690834 @default.
- W2980669947 cites W2147175196 @default.
- W2980669947 cites W2150612025 @default.
- W2980669947 cites W2157344759 @default.
- W2980669947 cites W2168847627 @default.
- W2980669947 cites W2228975584 @default.
- W2980669947 cites W2262434047 @default.
- W2980669947 cites W2316926066 @default.
- W2980669947 cites W2413899881 @default.
- W2980669947 cites W2537603665 @default.
- W2980669947 cites W2749818521 @default.
- W2980669947 cites W2751078671 @default.
- W2980669947 cites W2772476552 @default.
- W2980669947 cites W2796900808 @default.
- W2980669947 cites W2804483499 @default.
- W2980669947 cites W2808461388 @default.
- W2980669947 cites W2810943520 @default.
- W2980669947 cites W2811329572 @default.
- W2980669947 cites W2950479922 @default.
- W2980669947 cites W4230178784 @default.
- W2980669947 doi "https://doi.org/10.1016/j.tiv.2019.104685" @default.
- W2980669947 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31634544" @default.
- W2980669947 hasPublicationYear "2020" @default.
- W2980669947 type Work @default.
- W2980669947 sameAs 2980669947 @default.
- W2980669947 citedByCount "6" @default.
- W2980669947 countsByYear W29806699472020 @default.
- W2980669947 countsByYear W29806699472021 @default.
- W2980669947 countsByYear W29806699472022 @default.
- W2980669947 countsByYear W29806699472023 @default.
- W2980669947 crossrefType "journal-article" @default.
- W2980669947 hasAuthorship W2980669947A5003580737 @default.
- W2980669947 hasAuthorship W2980669947A5031445293 @default.
- W2980669947 hasAuthorship W2980669947A5039184690 @default.
- W2980669947 hasAuthorship W2980669947A5059256469 @default.
- W2980669947 hasAuthorship W2980669947A5065284334 @default.
- W2980669947 hasAuthorship W2980669947A5068582168 @default.
- W2980669947 hasAuthorship W2980669947A5069104759 @default.
- W2980669947 hasAuthorship W2980669947A5076408652 @default.
- W2980669947 hasAuthorship W2980669947A5090259400 @default.
- W2980669947 hasConcept C123012128 @default.
- W2980669947 hasConcept C126322002 @default.
- W2980669947 hasConcept C134018914 @default.
- W2980669947 hasConcept C161790260 @default.
- W2980669947 hasConcept C181199279 @default.
- W2980669947 hasConcept C185592680 @default.
- W2980669947 hasConcept C202751555 @default.
- W2980669947 hasConcept C2777318727 @default.
- W2980669947 hasConcept C2777411675 @default.
- W2980669947 hasConcept C2777477808 @default.
- W2980669947 hasConcept C2780422782 @default.
- W2980669947 hasConcept C2781128415 @default.
- W2980669947 hasConcept C55493867 @default.
- W2980669947 hasConcept C71924100 @default.
- W2980669947 hasConcept C98274493 @default.